华宝医药生物混合A(240020)利润分配表
| |
2026-06-30 |
2025-12-31 |
2025-06-30 |
2024-12-31 |
| 收入 |
-15,252,987.70 |
201,955,145.55 |
220,399,265.48 |
-159,279,699.64 |
| 利息合计 |
114,863.57 |
258,260.81 |
135,089.24 |
412,351.17 |
| 其中:存款利息收入 |
114,863.57 |
258,260.81 |
135,089.24 |
412,351.17 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-51,228,943.54 |
206,997,686.40 |
120,712,030.23 |
-122,157,267.56 |
| 其中:股票投资收益 |
-52,757,232.99 |
205,366,820.54 |
119,463,644.59 |
-128,747,071.70 |
| 基金投资收益 |
- |
- |
- |
- |
| 债券投资收益 |
- |
- |
- |
82,278.51 |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
1,528,289.45 |
1,630,865.86 |
1,248,385.64 |
6,507,525.63 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
35,488,331.86 |
-6,227,873.89 |
99,220,450.99 |
-38,400,178.91 |
| 其他收入 |
372,760.41 |
927,072.23 |
331,695.02 |
865,395.66 |
| 费用 |
4,244,177.93 |
8,612,606.91 |
4,187,506.03 |
13,371,193.27 |
| 管理人报酬 |
3,296,375.39 |
7,066,521.82 |
3,422,227.58 |
11,031,780.90 |
| 基金托管费 |
549,395.93 |
1,177,753.62 |
570,371.29 |
1,838,630.09 |
| 销售服务费 |
293,373.39 |
161,862.80 |
108,309.09 |
326,272.13 |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中:卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
105,013.78 |
206,468.67 |
86,598.07 |
174,510.00 |
| 利润总额 |
-19,497,165.63 |
193,342,538.64 |
216,211,759.45 |
-172,650,892.91 |
欢迎访问证券之星!请点此与我们联系 版权所有: Copyright © 1996-年